Findings on Postpartum Depression Detailed by Investigators at Peking University First Hospital (Efficacy of a Single Low Dose of Esketamine After Childbirth for Mothers With Symptoms of Prenatal Depression: Randomised Clinical Trial).

A recent study conducted at Peking University First Hospital in Beijing, China, investigated the efficacy of a single low dose of esketamine in reducing postpartum depression in mothers with prenatal depression. The study involved 364 mothers who were randomly assigned to receive either esketamine or a placebo after childbirth. The results showed that the prevalence of major depressive episodes at 42 days postpartum was significantly lower in the esketamine group compared to the placebo group. Although the esketamine group experienced more neuropsychiatric adverse events, these symptoms were transient and did not require drug intervention. This research suggests that a single low dose of esketamine after childbirth may be effective in reducing postpartum depression in mothers with prenatal depression. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)